When dendritic cells (DCs) encounter signals associated with infection or inflammation, they become activated and undergo maturation. Mature DCs are very efficient at presenting antigens captured in association with their activating signal but fail to present subsequently encountered antigens, at least in vitro. Such impairment of MHC class II (MHC II) antigen presentation has generally been thought to be a consequence of down-regulation of endocytosis, so it might be expected that antigens synthesized by the DCs themselves (for instance, viral antigens) would still be presented by mature DCs. Here, we show that DCs matured in vivo could still capture and process soluble antigens, but were unable to present peptides derived from these antigens. Furthermore, presentation of viral antigens synthesized by the DCs themselves was also severely impaired. Indeed, i.v. injection of pathogen mimics, which caused systemic DC activation in vivo, impaired the induction of CD4 T cell responses against subsequently encountered protein antigens. This immunosuppressed state could be reversed by adoptive transfer of DCs loaded exogenously with antigens, demonstrating that impairment of CD4 T cell responses was due to lack of antigen presentation rather than to overt suppression of T cell activation. The biochemical mechanism underlying this phenomenon was the down-regulation of MHC IIpeptide complex formation that accompanied DC maturation. These observations have important implications for the design of prophylactic and therapeutic DC vaccines and contribute to the understanding of the mechanisms causing immunosuppression during systemic blood infections. 2). In their immature state, DCs are highly endocytic and express low amounts of MHC II molecules on their plasma membrane. Pathogenassociated compounds such as those recognized by Toll-like receptors (TLRs) activate immature DCs, which then undergo dramatic phenotypic changes that culminate in the acquisition of a ''mature'' phenotype. Mature DCs down-regulate macropinocytosis and phagocytosis, although they retain their micropinocytic activity (3, 4). Mature DCs accumulate long-lived surface MHC II-peptide complexes, derived from antigens contained within the endosomal compartments at the time of activation (5-10, 55). Such antigens correspond to proteins captured from the extracellular medium (exogenous), or those synthesized by the DCs themselves (endogenous). The latter include components of the endocytic route, plasma membrane proteins, and even cytosolic proteins transferred to endosomal compartments by autophagocytosis (1). Down-regulation of MHC II-peptide complex turnover allows long-term presentation of antigens captured, or synthesized, at the time of activation (''antigenic memory'') (2).
2). In their immature state, DCs are highly endocytic and express low amounts of MHC II molecules on their plasma membrane. Pathogenassociated compounds such as those recognized by Toll-like receptors (TLRs) activate immature DCs, which then undergo dramatic phenotypic changes that culminate in the acquisition of a ''mature'' phenotype. Mature DCs down-regulate macropinocytosis and phagocytosis, although they retain their micropinocytic activity (3, 4) . Mature DCs accumulate long-lived surface MHC II-peptide complexes, derived from antigens contained within the endosomal compartments at the time of activation (5) (6) (7) (8) (9) (10) 55) . Such antigens correspond to proteins captured from the extracellular medium (exogenous), or those synthesized by the DCs themselves (endogenous). The latter include components of the endocytic route, plasma membrane proteins, and even cytosolic proteins transferred to endosomal compartments by autophagocytosis (1) . Down-regulation of MHC II-peptide complex turnover allows long-term presentation of antigens captured, or synthesized, at the time of activation (''antigenic memory'') (2) .
Once DCs mature, they lose their capacity to present newly encountered antigens (2) . This is usually attributed to downregulation of endocytosis, but it is unclear whether other factors downstream of antigen uptake also contribute to poor presentation of new antigens. It is also important to note that DC maturation has been primarily characterized by using in vitro culture systems, and it is unclear whether DCs maturing in vivo also down-regulate MHC II presentation (11) (12) (13) . This is an important question because the outcome of vaccination strategies based on antigen targeting to DCs (14) (15) (16) (17) , or on loading of DCs with tumor antigens ex vivo (18) , might be affected by the maturational status of the DCs. Furthermore, bacterial infections of the blood (sepsis) or parasite infections (e.g., malaria) can cause systemic DC maturation (19) (20) (21) and, concomitantly, immunosuppression (21) (22) (23) . Defining the role of systemic DC maturation on this immunosuppression, and the mechanisms controlling MHC II antigen presentation by DCs, might provide strategies for restoring immunocompetence.
Here, we demonstrate that activated DCs are no longer capable of presenting newly encountered antigens via MHC II either in vitro or in vivo. This is due primarily to impaired formation of new MHC II-peptide complexes in mature DCs, rather than to down-regulation of antigen uptake or processing. Indeed, presentation of an endogenous viral antigen was also impaired in mature DCs infected with influenza virus. Furthermore, mice injected intravenously with TLR ligands, which causes systemic DC maturation, could not induce CD4 T cell responses against subsequently inoculated soluble antigen. This immunosuppression could be reversed by adoptive transfer of DCs preloaded with peptide antigen, showing that lack of T cell proliferation in the TLR ligand-treated mice was due to impaired antigen presentation rather than to general suppression of T cell activation. Our results identify a likely mechanism responsible for the immunosuppression that accompanies systemic blood infections and provides important clues for the rational design of vaccination strategies and DC-based immunotherapeutic treatments.
Results

Systemic Activation of DCs Prevents MHC II-Restricted Presentation of
Subsequently Encountered Soluble Antigens. Virtually all of the ''conventional'' (CD11c high ) DCs contained in mouse spleens, and approximately one-half of those contained in the lymph nodes, are ''resident'' DC types that develop directly within the lymphoid organs from pre-DC precursors (refs. 24 and 25; reviewed in ref. 26) . These DCs have a classical immature phenotype, characterized by high phagocytic activity, accumulation of MHC II molecules in endosomal compartments, and relatively low surface expression of MHC II, CD86, and CD40 ( Fig. 1A and data not shown) (27) . Intravenous injection of TLR ligands such as cytosine-phosphate-guanine-rich oligonucleotide 1668 (CpG), LPS, or polyinosinic:polycytidylic acid, or infection with the malaria parasite, Plasmodium berghei, causes systemic activation of these resident DCs, which then up-regulate their expression of maturation markers ( Fig. 1 A and data not shown) (19, 21, 27) .
To assess the effect of in vivo preactivation on the antigenpresenting function of DCs, we purified splenic DCs from control mice, or mice treated with CpG 9 h earlier, and tested their capacity to present soluble ovalbumin (OVA) to naive OT-II cells. DCs from normal mice presented the antigen and, as they spontaneously matured during the assay, stimulated OT-II proliferation (Fig. 1B) . Injection of CpG had a dosedependent inhibitory effect on induction of OT-II proliferation (Fig. 1B) . DCs from control or CpG-pretreated mice induced comparable OT-II responses if they were incubated with synthetic OVA 323-339 peptide to bypass the requirement for intracellular antigen processing [supporting information (SI) Fig.  6A ]. Furthermore, DCs from control or CpG-pretreated actmOVA mice, which express a transgenic membrane-bound form of OVA, also induced OT-II proliferation similarly (SI Fig. 6B ). Therefore, DCs from CpG-pretreated animals were impaired in their capacity to process and present newly encountered antigens, but not in their capacity to stimulate T cells (if peptide loaded or expressing the antigen).
One mechanism that might account for the poor presentation of OVA by mature DCs could be poor antigen capture. Indeed, we have previously demonstrated that mature DCs cannot cross-present cell-associated antigens via MHC I, nor present them via MHC II, because they down-regulate phagocytosis, the mechanism involved in uptake of cells (21) . Soluble OVA, however, can be captured by pinocytosis, a form of endocytosis that persists in mature DCs (3, 4) . Therefore we assessed uptake and degradation of soluble OVA by DCs from control or CpG-treated mice. Both groups of DCs endocytosed comparable amounts of a fluorescent form of soluble OVA coupled to the pH-insensitive fluorochrome Alexa 488 (Fig. 1C) , and generated with comparable kinetics fluorescent degradation products on endocytosis of DQ-OVA, a self-quenched form of fluorescent OVA (Fig. 1D ). Endocytosis and degradation of soluble antigen was thus unaffected in mature DCs.
To more directly compare the ability of immature and mature DCs to load their MHC II molecules with newly encountered antigens, we used the mAb AW3.1, which recognizes the hen egg lysozyme (HEL)-derived peptide HEL [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] bound to I-A k (28, 29) . We purified splenic DCs from control or CpG-pretreated CBA mice, incubated them with or without HEL for 25 h, and measured accumulation of I-A k -HEL [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] complexes on the cell surface by flow cytometry. AW3.1 showed some cross-reactivity with I-A k molecules devoid of HEL [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] . This caused a shift in the FACS profile of the control DCs incubated without HEL at the end of the 25 h of incubation ( Fig. 2A) because of the increase in total surface expression of MHC II during DC maturation (Fig. 1 A) . Accumulation of I-A k -HEL [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] complexes on the surface of control DCs incubated with HEL was clearly observed as a shift in the flow cytometry profile above this background (Fig. 2 A) . In contrast, the flow cytometry profile of AW3.1 reactivity hardly increased above the background staining in CpG-pretreated DCs incubated with or without HEL (Fig. 2 A) , indicating that mature DCs did not generate I-A k -HEL [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] complexes during the 25-h incubation with the antigen. This confirmed that mature DCs are inefficient at loading their MHC II molecules with peptides derived from antigens encountered after reaching the mature state.
Splenic DCs can be subdivided into two major groups, CD8 ϩ DCs and CD8
Ϫ DCs (30, 31) . It has been shown that the CD8 ϩ DCs are less efficient at MHC II presentation of antigens captured by phagocytosis or by the surface receptor CD205 (17, 32) . However, it is unclear whether this is caused by an overall deficiency in formation of MHC II-peptide complexes in the CD8 ϩ DCs or because of poor delivery of antigen into the MHC II presentation pathway. To address this, we compared the formation of I-A k -HEL [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] complexes in the CD8 ϩ and CD8 Ϫ DCs. As shown previously (28, 33) , both subsets presented comparable amounts of the I-A k -HEL 48-62 complexes (Fig. 2B ). Furthermore, both subsets were equally impaired in formation of new complexes once they had reached the mature stage (data not shown).
Mature DCs Cannot Present Newly Encountered Endogenous Viral
Antigens via MHC II. To further investigate whether the inability of mature DCs to present newly encountered antigens was attributable to lack of antigen capture, we measured the presentation of an endogenous viral antigen. We purified DCs from control and CpG-pretreated BALB/c mice and infected them in vitro with influenza virus. The cells were washed and then incubated with carboxylfluorescein diacetate succinimidyl ester (CFSE)-labeled HNT cells, which recognize the influenza hemagglutinin (HA) 126 -138 peptide bound to I-A d molecules. As a membrane protein, HA is processed in endosomal compartments and is therefore readily presented via MHC II by influenza-infected cells. Thus, the infected immature DCs obtained from control animals presented the viral epitope and, as they matured in vitro, induced HNT proliferation (Fig. 3A) . In contrast, the already mature DCs from CpG-treated animals induced little HNT proliferation (Fig. 3A) . The two sets of DCs presented an MHC I-restricted epitope derived from HA with similar efficiency, as measured by parallel assessments of proliferation of H2-K drestricted, HA 512-520 -specific CL4 T cells (Fig. 3A) . This discarded the possibility that differences in viral infectivity, or in the level of expression of HA in the infected cells, were responsible for the contrast in presentation of the HNT epitope between the two DC groups. The CD8 ϩ and CD8 Ϫ DC subsets were comparable in their capacity to present HA via MHC II, and this presentation was equally impaired in both subsets on maturation (Fig. 3B) .
Impaired Antigen Presentation Is Caused in Mature DCs by Down-
Regulation of MHC II Synthesis. Our results demonstrate that mature DCs can no longer present newly encountered antigens on their MHC II molecules, and that the main checkpoint for the lack of presentation is not antigen availability. An alternative mechanism for this phenomenon might be down-regulation of MHC II synthesis (2, 5, 7, 8, 34, 35) , which would impair formation of new MHC II-peptide complexes in mature DCs. Indeed, MHC II synthesis was drastically down-regulated in DCs matured in vivo by CpG injection, as measured by metabolic labeling and immunoprecipitation of MHC II molecules, in the three mouse strains analyzed in this study (Fig. 4) . Synthesis of MHC I molecules did not decrease on maturation (data not shown) (5, 7, 8, 34) , consistent with maintenance of MHC I presentation in mature DCs (Fig. 3B) .
DC Preactivation Impairs MHC II Presentation in
Vivo. An implication of the effect of DC preactivation on subsequent antigen presentation is that conditions that promote systemic DC maturation may limit the efficacy of vaccination. To test this hypothesis, we compared the responses of OT-II cells in mice inoculated with OVA together with one of two different doses of CpG, with those in mice that first received CpG and were then injected with OVA, 3 or 9 h later. All mice were injected i.v. with CFSElabeled OT-II cells immediately after the OVA injection, and the proliferation of these T cells in the spleen was determined 2.5 days later. The extent of OT-II proliferation decreased slightly in mice treated with CpG 3 h before the OVA challenge, and was severely impaired in mice that received CpG 9 h before OVA (Fig. 5A) . These results show that induction of systemic DC maturation can prevent presentation of subsequently encoun- tered vaccine antigens in vivo. To test whether this immunosuppressed state could be reversed by providing DCs presenting antigen, we purified mature DCs from CpG-pretreated mice and incubated them in vitro with synthetic OVA 323-339 peptide. The DCs were washed and injected i.v. in control or CpG-pretreated mice. CFSE-labeled OT-II cells were then inoculated in separate injections. Measurement of OT-II proliferation by FACS 2.5 days later showed that the immunosuppression caused by systemic DC maturation could be reversed by adoptive transfer of DCs presenting the antigen (Fig. 5B) . Furthermore, because the transferred DCs were from CpG-pretreated animals, this experiment confirmed that such DCs can activate T cells in vivo, provided they present the appropriate MHC II-peptide complexes.
Discussion
In this study, we have shown that DCs matured in vivo by CpG lose their ability to present newly encountered antigens via MHC II. Animals in which pathogen-associated compounds had caused systemic DC maturation were thus unable to present new antigens such as OVA to CD4 T cells and induce their proliferation. Efficient T cell proliferation in CpG-pretreated mice vaccinated with DCs loaded ex vivo with synthetic peptide antigens indicated that CpG injection had not caused overt suppression of CD4 T cell activation in these mice. Similar effects were induced by injection of other TLR ligands [e.g., LPS or polyinosinic:polycytidylic acid (data not shown)] and by blood infections with pathogens such as the malaria parasite (data not shown), which also cause systemic DC maturation (27) .
We have previously shown that systemic DC preactivation impaired cross-presentation and the stimulation of CD8 ϩ T cell responses against herpes simplex virus and influenza virus, which are probably induced by cross-priming (21). Impairment of cross-presentation of viral antigens was attributed chiefly to down-regulation of phagocytosis, which prevented mature DCs from capturing infected cells. Indeed, mature DCs could present endogenous viral antigens via MHC I if infected (21) (Fig. 3) , indicating that their endogenous MHC I presentation pathway was operative. Down-regulation of phagocytosis is also the primary cause of impairment of MHC II presentation of cellassociated antigens by mature DCs (21) . However, lack of antigen capture cannot be the main cause of impaired MHC II presentation of viral antigens seen here, because mature DCs efficiently presented these same antigens via the MHC I pathway, indicating synthesis of the antigen by the DCs.
Presentation of soluble antigens such as OVA and HEL was likewise impaired in mature DCs even though these cells still endocytosed and processed this form of antigen. Soluble proteins can be internalized by receptor-mediated endocytosis or fluid-phase pinocytosis. One candidate endocytic receptor might be the mannose receptor, which efficiently captures OVA and, in bone marrow-derived DCs, delivers this antigen to specialized compartments for MHC I cross-presentation and away from the MHC II presentation pathway (36) . However, this receptor is unlikely to play a major role in the uptake of the antigens assessed in our study. First, HEL is a nonglycosylated protein. Second, the mannose receptor is not expressed in splenic DCs (37) , or is only expressed in a subgroup of the CD8 ϩ DC population (36) , yet all of the CD8 ϩ DCs, and also the CD8 Ϫ DCs, capture and present soluble OVA in vivo and in vitro (32, 38) . Fluid-phase endocytosis is more likely to be involved in capture of soluble OVA and HEL, and because micropinocytosis remains largely unchanged in mature DCs (3, 4) , uptake via this mechanism can explain why the rate of uptake and degradation of OVA was little affected by DC maturation.
Regardless of which specific mechanism is involved, it is clear that lack of endocytosis cannot by itself explain the inability of mature DCs to present newly encountered antigens via the MHC II pathway. The mechanism responsible for this impairment is more likely the down-regulation of MHC II synthesis that accompanies DC maturation, which prevented formation of new MHC II-peptide complexes in mature DCs (2, 5, 7, 8, 34, 35) .
The experiments shown here were carried out by using the two major ''lymphoid organ-resident'' DC populations, namely the 
CD8
ϩ and CD8 Ϫ DCs (26) . MHC II presentation of antigens captured by phagocytosis or by some C-type lectin receptors is carried out more efficiently by CD8 Ϫ than by CD8 ϩ DCs, whereas MHC I cross-presentation of these same antigens is carried out almost exclusively by CD8 ϩ DCs (17, 32) . This has led to the suggestion that the MHC II antigen presentation machinery is relatively inefficient in CD8 ϩ DCs (17) . Our analysis of presentation of soluble HEL, or of the endogenous viral antigen HA, does not support this hypothesis. In line with previous studies (2, 27, 28, 33, 39) , our results confirm that overall formation of MHC II-peptide complexes is comparable in CD8 Ϫ and CD8
ϩ DCs. Therefore, it appears more likely that the difference in presentation of antigens internalized by phagocytosis or C-type lectin receptors between the two DC subsets is caused by differential delivery of antigens captured by these two mechanisms to compartments for MHC II presentation (36) . Direct analysis of antigen trafficking will be required to confirm or discard this hypothesis (26) . In any case, both lymphoid organ-resident DC types down-regulated MHC II presentation of antigens encountered after maturation.
Our results contribute to the understanding of the mechanisms of immunosuppression associated with blood infections such as sepsis (22) and malaria (23) . In most scenarios of infection, down-regulation of antigen presentation in mature DCs should have no deleterious consequences because the number of DCs that respond to a given pathogen is probably small. Therefore, each pathogen encounter probably leaves enough immature DCs ready to respond to subsequent challenges. However, systemic DC maturation induced by sepsis or malaria infection depletes the immune system of DCs capable of responding to new infections and thus causes immunosuppression. Such an effect might contribute to poor vaccination outcomes, and to the prevalence of Burkitt's lymphoma, in malariaendemic areas (40, 41) , the latter thought to be a consequence of compromised control of Epstein-Barr virus infection. We could reverse this effect in our experimental system by injecting the immunocompromised mice with DCs presenting the antigen. Similar approaches, or restoration of antigen presentation by other means, might recover immunocompetence in individuals suffering sepsis or malaria infection. This applies to presentation via MHC II and also to MHC I cross-presentation (21) . Importantly, however, approaches that might work to induce MHC I presentation in already mature DCs, such as induction of endogenous expression of the antigen in the DCs, may not work as a strategy to induce MHC II presentation.
Our results also have implications for the design of DC-based prophylactic and therapeutic vaccines. First, vaccination strategies consisting of antigen targeting to DC receptors (14) (15) (16) (17) should target immature DCs for maximum efficacy. Second, our observations help to understand why vaccines that combine TLR ligands covalently associated with an antigen are more efficient than those in which the two components are separate, even when administered simultaneously (15, 42) . In the latter case, the TLR ligand may reach DCs that have not yet encountered the antigen, inducing their maturation and thus preventing their participation in antigen presentation. Finally, it is important to note that immunotherapeutic approaches (18) consisting of inoculation of DCs that are first induced to mature in vitro, and then transfected with nucleic acids encoding tumor antigens (43) , might result in DCs presenting the antigens via MHC I but not via MHC II (44) , although evidence to the contrary has been reported as well (45, 46) . Lack of induction of helper T cells might lead to poor induction of protective cytotoxic T lymphocyte immune responses (47) or even induce tolerance (48) , so caution must be exerted when employing this strategy.
Methods
Mice. The mice used were 6-to 12-week-old C57BL/6 (H-2 b ), BALB/c (H-2 d ), CBA (H-2 k ), and transgenic strains OT-II (49), act-mOVA (50), HNT (51) , and CL4 (52) . All mice were bred and maintained under specific pathogen-free conditions following institutional guidelines. Where indicated, mice were injected i.v. in the tail vein with 2.5-50 nmol of synthetic phosphorothioated CpG1668 (GeneWorks, Hindmarsh, Australia) dissolved in PBS.
DC Purification, Culture, and Flow Cytometric Analysis. DCs were purified from spleens and analyzed by flow cytometry as described in ref. 53 . DCs were cultured in the presence of 10 ng/ml granulocyte/macrophage colony-stimulating factor (PeproTech, Madison, WI) and 0.5 M CpG1668 (GeneWorks) as described in ref. 27 . (29) ], washed, and analyzed by flow cytometry. To determine the MLF values of the samples, it was necessary to discard rare events (Ͻ2% of the population) that gave extreme values, so the MLF values were calculated by gating on the area of the plot that contained 98% of the events.
Metabolic Labeling. Metabolic labeling, immunoprecipitations, and SDS/PAGE analysis were carried out as described in ref. 8 . MHC II was immunoprecipitated with a rabbit serum raised against the cytoplasmic portion of I-A␣ (54).
Influenza Virus Infection and Proliferation of Virus-Specific T Cells. DC preparations from control or CpG-pretreated BALB/c mice were washed three times in serum-free RPMI 1640, infected with 5 pfu per cell A/PR/8/34 (H1N1) (Mount Sinai strain; a gift from L. Brown, University of Melbourne, Melbourne, Australia), and purified as described in ref. 21 . The indicated numbers of infected DCs were then plated in V-bottom 96-well plates (Costar) with 5 ϫ 10 4 CFSE-labeled HNT or CL4 transgenic T cells. Proliferation was determined 60 h later. Each determination was performed in duplicate.
Injection of DCs Loaded with OVA Peptide into CpG-Pretreated Mice.
DCs were purified from CpG-pretreated C57BL/6 mice, incubated without or with 1 g/ml synthetic OVA 323-339 for 45 min at 37°C, and washed. A total of 2 ϫ 10 6 unloaded or peptideloaded DCs, and 2 ϫ 10 6 CFSE-labeled OT-II cells, were injected i.v. into opposite tail veins of control mice or mice pretreated with CpG 0, 3, or 9 h earlier. In vivo T cell proliferation was determined 60 h later as described in ref. 21 .
